Renascience Inc.
株式会社レナサイエンス
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4889
FY2025 (Mar 2026) · J-GAAP · parent-only (non-consolidated) Source: filing S100YGXR
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 93.7% |
|---|---|
| Operating margin | -520.6% |
| Net margin | -439.5% |
| Return on equity | -12.0%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | -11.2% |
| Revenue growth (YoY) | -48.3% |
| EPS (basic) | −¥23.39 |
| EPS growth (YoY) | -362.2% |
| Current ratio | 19.40x |
| Equity ratio | 94.5% |
| Book value / share | ¥240.26 |
| Free cash flow | —Not in the filing: capital expenditure (PP&E + intangible assets) |